A method for coating an implantable medical device to form a drug delivery system, the method comprising: a. providing an implantable medical device having a surface; b. depositing a first layer comprising a taxane agent on the surface of the medical device, the depositing a first layer comprising: i. applying to the surface a first solution comprising a first solvent and the taxane agent dispersed in the first solvent, wherein the taxane agent comprises paclitaxel and wherein the first solution does not contain a polymer; ii. evaporating the first solvent; iii. repeating the application and evaporation until the first layer contains between 0.05 and 1.00 μg of paclitaxel per mm 2 of the surface, wherein at least 20% of the paclitaxel is in the form of dihydrate paclitaxel and wherein at least a portion of the paclitaxel is in the form of anhydrous or amorphous paclitaxel; c. depositing a second layer comprising a biodegradable elastomer over the first layer on the medical device, depositing the second layer comprising: i. applying to the first layer a second solution comprising a second solvent and a biodegradable elastomer dispersed in the second solvent, the biodegradable elastomer having a molecular weight of 75,000 - 240,000 Da; ii. evaporating the second solvent; iii. repeating the application and evaporation until the weight of the biodegradable elastomer in the second layer is between 1 and 20 times greater than the weight of the taxane agent in the first layer; wherein the second solvent is acetone or tetrahydrofuran. a. providing an implantable medical device having a surface; b. depositing a first layer comprising a taxane agent on the surface of the medical device, the depositing a first layer comprising: i. applying to the surface a first solution comprising a first solvent and the taxane agent dispersed in the first solvent, wherein the taxane agent comprises paclitaxel and wherein the first solution does not contain a polymer; ii. evaporating the first solvent; iii. repeating the application and evaporation until the first layer contains between 0.05 and 1.00 μg of paclitaxel per mm 2 of the surface, wherein at least 20% of the paclitaxel is in the form of dihydrate paclitaxel and wherein at least a portion of the paclitaxel is in the form of anhydrous or amorphous paclitaxel; i. applying to the surface a first solution comprising a first solvent and the taxane agent dispersed in the first solvent, wherein the taxane agent comprises paclitaxel and wherein the first solution does not contain a polymer; ii. evaporating the first solvent; iii. repeating the application and evaporation until the first layer contains between 0.05 and 1.00 μg of paclitaxel per mm 2 of the surface, wherein at least 20% of the paclitaxel is in the form of dihydrate paclitaxel and wherein at least a portion of the paclitaxel is in the form of anhydrous or amorphous paclitaxel; c. depositing a second layer comprising a biodegradable elastomer over the first layer on the medical device, depositing the second layer comprising: i. applying to the first layer a second solution comprising a second solvent and a biodegradable elastomer dispersed in the second solvent, the biodegradable elastomer having a molecular weight of 75,000 - 240,000 Da; ii. evaporating the second solvent; iii. repeating the application and evaporation until the weight of the biodegradable elastomer in the second layer is between 1 and 20 times greater than the weight of the taxane agent in the first layer; i. applying to the first layer a second solution comprising a second solvent and a biodegradable elastomer dispersed in the second solvent, the biodegradable elastomer having a molecular weight of 75,000 - 240,000 Da; ii. evaporating the second solvent; iii. repeating the application and evaporation until the weight of the biodegradable elastomer in the second layer is between 1 and 20 times greater than the weight of the taxane agent in the first layer;